Computational and Mathematical Methods in Medicine

Research Article

[Retracted] Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient’s Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis

Table 1

Baseline characteristics of the included literature.
AuthorYearPhaseStudy typeMedian age (range)TreatmentSubtypes includedDefinition pCRMeasure of recurrenceSample sizepCR (%)EFSOS
With pCRWithout pCRWith pCRWithout pCR
Zelnak2015IIRetrospective49 (36-64)Nab-paclitaxel followed by vinorelbine and trastuzumabHER2ypT0/is ypN0DFS2713/27 (48.1)2/133/14
Mayer2015IIRetrospective46 (26-64)Paclitaxel/trastuzumab (TH) or vinorelbine/trastuzumab (NH)HER2ypT0/is ypN0RFS8014/80 (17.5)3/1421/66
Gonzalez2015RetrospectiveTrastuzumab-based NSTHER2ypT0/is ypN0RFS589203/589 (34.5)7/20354/3865/20333/386
Cynthia2015Retrospective49 (26-72)Neoadjuvant trastuzumab-based chemotherapyHER2ypT0/is ypN0DFS244119/244 (48.8)21/11940/1257/11923/125
Bear2015IIIProspectiveDocetaxel with capecitabine/gemcitabine/neoadjuvant doxorubicin and cyclophosphamideHER2ypT0/is ypN0DFS1180368/1180 (31.2)52/368243/81229/369167/812
Ko2015Retrospective43.8 (23-72)NACAllypT0/is ypN0RFS17437/174 (21.3)3/3738/137
Liu2015Retrospective53 (23-70)Trastuzumab-based NATHER2ypT0/is ypN0EFS10841/108 (38.0)4/4124/67
Taher2015IIProspective43 (25-60)Neoadjuvant chemotherapy using epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin and docetaxel, plus trastuzumab if HER2 positive.HER2ypT0/is ypN0DFS8026/80 (32.5)1/2623/541/265/54
Groheux2016Retrospective51 (27-78)EC-D/SIMTNBCypT0/is ypN0EFS7829/78 (37.2)1/2924/49
Shani2016ProspectiveAnthracycline- and taxane-based neo-adjuvant chemotherapyTNBCypT0/is ypN0RFS7739/77 (50.6)5/3922/38
Cynthia2016Retrospective48.9 (42.2-56.7)NACAllypT0/is ypN0DFS1639466/1639 (28.4)91/466366/117337/466320/1173
Li2016RetrospectiveTaxane-based or anthracycline-based neoadjuvant chemotherapyTNBCypT0/is ypN0RFS18642/186 (22.6)5/4244/144
Zhang2016IIProspective47 (24-73)Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapyTNBCypT0/is ypN0RFS8723/87 (26.4)1/2328/641/2321/64
Shao2016RetrospectiveNACTTNBCypT0/is ypN0PFS5014/50 (28)2/1425/362/1425/61
Choi2017Retrospective44 (22-68)Anthracycline and taxane-based NACAllypT0/is ypN0DDFS353198/353 (56.1)33/19869/15515/19837/155
Bignon2017ProspectiveNACAllypT0/is ypN0695192/695 (27.6)11/19295/503
Bignon2017Retrospective39 (25-59)Anthracycline-based neoadjuvant chemotherapyTNBCypT0/is ypN0DFS5323/53 (43.4)8/2321/301/2314/30
Biswas2017Retrospective51 (21-88)NACTTNBCypT0/is ypN0DFS20267/202 (33.2)5/6780/13518/6771/135
Viala2018Retrospective50NACAllypT0/is ypN0PFS327107/327 (32.7)8/10761/2206/10746/220
Sharma2018Prospective51Neoadjuvant carboplatin plus docetaxelTNBCypT0/is ypN0RFS183100/183 (54.6)10/10028/836/10017/83
Gass2018RetrospectiveAnthracycline/platinum/taxane-based neoadjuvant chemotherapyTNBCypT0/is ypN0DFS12156/121 (46.3)11/5613/65
Resende2019RetrospectiveNACAllypT0/isDFS31043/310 (13.9)4/4374/2672/4353/267
Laura2020IIRetrospective49 (23-77)Neoadjuvant therapy consisting of taxane treatment followed by doxorubicin and cyclophosphamideHER2ypT0/is ypN0EFS950330/950 (34.7)26/330272/620
Esgueva2020Prospective53.8 (24–95)NATAllypT0/is ypN0DFS646136/646 (21.1)13/136201/5107/136219/510
Hong2020Retrospective55NATAllypT0/isDFS32891/328 (27.7)9/9193/23715/9137/237